FIELD: medicine, biotechnology. SUBSTANCE: invention relates to immunogenic composition containing chimeric HIV polypeptide, method for induction of immune response to HIV 1 and HIV 1/2, chimeric polypeptide HIV 1 and HIV 1/2, DNA molecule encoding chimeric polypeptide, plasmid vector for expression of chimeric polypeptide, polyclonal antibodies raised to HIV 1 or HIV 1/2 and diagnostic test-system for detection of antibodies raised to HIV 1 and HIV 2. Invention involves immunogenic composition based on chimeric polypeptides HIV 1 or HIV 1/2 representing full-sized protein p24 fused with immunodominant fragment gp 41 of site 575-616 or taken among them (rec 24-41) or fused with immunodominant fragment gp 36 of the same site or taken among them (rec 24-36). Indicated composition is able to induce the strong immune response to HIV 1 or HIV 2. Invention involves also the gene construction able to expression of indicated chimeric polypeptides in E. coli cells and diagnostic test-system for detection of antibodies raised to HIV 1 and HIV 2. The advantage of invention involves the development of gene construction allowing expression the chimeric recombinant protein that contains a full-sized polypeptide as a component of a single polypeptide chain and related by its conformation to viral protein p24 and immunogenic protein fragment of HIV 1 or HIV 2 envelope. Indicated recombinant proteins are able to induce strong immune response to HIV 1 or HIV 1/2 that allows using these chimeric polypeptides both for creation of diagnostic test-systems and for their recommendation for development of vaccine preparations. EFFECT: valuable properties of composition. 18 cl, 3 tbl, 5 dwg, 10 ex
Title | Year | Author | Number |
---|---|---|---|
VACCINE AGAINST HIV/AIDS | 2010 |
|
RU2475264C2 |
IMMUNOGENIC COMPOSITIONS BASED ON SYNTHETIC PEPTIDES MIMICKING ACTUAL DETERMINANTS OF HIV1 gp120 | 2014 |
|
RU2577132C1 |
IMMUNOPROPHYLACTIC VACCINE AGAINST HIV BASED ON HIV-SPECIFIC ANTIBODIES | 2008 |
|
RU2505604C2 |
RECOMBINANT CHIMERICAL nTBI POLYPEPTIDE-IMMUNOGEN WITH ABILITY TO INDUCE NEUTRALIZING ANTIBODIES TO TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS AND INTENDED FOR USE AS COMPONENT OF VACCINE AGAINST HIV-1 | 2016 |
|
RU2642258C1 |
METHOD FOR PREDICTING MEDICINAL ALLERGY | 2002 |
|
RU2229721C2 |
IMMUNOGENIC COMPOSITION CONTAINING SYNTHETIC PEPTIDES REPEATING SEQUENCE OF V3-LOOP OF SHELL PROTEIN GP120 HIV1 | 2017 |
|
RU2694576C2 |
HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
NEW SOLUBLE AND STABILISED TRIMERIC FORM OF GP41 POLYPEPTIDES | 2004 |
|
RU2390525C2 |
RECOMBINANT PLASMID DNA PUE 41 ENCODING ENVELOPE PROTEIN FRAGMENTS GP 120 AND GP 41 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, AND A STRAIN OF BACTERIUM ESCHERICHIA COLI-A PRODUCER OF ENVELOPE PROTEIN FRAGMENTS GP 120 AND GP 41 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 | 1990 |
|
SU1766070A1 |
ANTIBODY OR FRAGMENT THEREOF, HAVING NEUTRALISING EFFECT ON HIV, BUT NOT ON IL2 | 2005 |
|
RU2393873C2 |
Authors
Dates
2003-10-20—Published
2001-08-16—Filed